Clinical Trials Browser

Pathologic Complete Response

Nasopharyngeal Carcinoma

Breast Neoplasms

Rectal Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Rectal Neoplasms Malignant

Locally Advanced Rectal Cancer (LARC)

Breast Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Carcinoma, Hepatocellular

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

Locally Advanced Low Rectal Adenocarcinoma

Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

Colorectal Neoplasms

Nasopharyngeal Cancinoma (NPC)

Rectal Neoplasms

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Stomach Neoplasms

Colonic Neoplasms

Rectal Neoplasms

Breast Neoplasms

Breast Neoplasms

Nasopharyngeal Carcinoma

Rectal Neoplasms

Nasopharyngeal Carcinoma

Pancreatic Cancer Resectable

Stomach Neoplasms

Colonic Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Solid Tumors

Stomach Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Breast Neoplasms

Rectal Neoplasms

Rectal Neoplasms

Pancreatic Cancer Non-resectable

Stomach Neoplasms

Rectal Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Pancreatic Neoplasms

Neoplasm Metastasis, Colorectal Neoplasms

Colorectal Neoplasms

Stomach Neoplasms

Esophageal Squamous Cell Carcinoma

MSI-H Colorectal Cancer

Colorectal Neoplasms

Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer

Colorectal Neoplasms

Clinical Trials

MEND-IT II

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer

EVOLVE-BDT

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

IMMUNOSTAR

BRIGHT

ARIEL-ENGIC

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

Cocktail-001

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

CAPTURE

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma

A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer

EC-CRT-008

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial

A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer

Calorite

A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults

FDZL-GC003

TRACER

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer

TAUTEM-T1

Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer

Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

AK104-IIT-13

Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD